The dual function of hepatic SOCS3 in insulin resistance in vivo

Genes to Cells

Volumn 12, Issue 2, 2007, Pages 143-154

  Torisu, Takehiro ^a,b   Sato, Naoichi ^a   Yoshiga, Daigo ^a   Kobayashi, Takashi ^a   Yoshioka, Tomoko ^a   Mori, Hiroyuki ^a   Iida, Mitsuo ^b   Yoshimura, Akihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; SALICYLATE SODIUM; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; GENE DELETION; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION; INFLAMMATION; INSULIN RESISTANCE; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

MUS;

EID: 33846512401     PISSN: 13569597     EISSN: 13652443     Source Type: Journal    
DOI: 10.1111/j.1365-2443.2007.01044.x     Document Type: Article

References (38)

1. Banks, A., Li, J., Mckeag, L., Hribal, M.L., Kashiwada, M., Accili, D. & Rothman, P.B. (2005) Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J. Clin. Invest. 115, 2462-2471.
2. Chen, K., Li, F., Li, J., Cai, H., Strom, S., Bisello, A., Kelley, D.E., Friedman-Einat, M., Skibinski, G.A., McCrory, M.A., Szalai, A.J. & Zhao, A.Z. (2006) Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat. Med. 12, 425-432.
3. Chinen, T., Kobayashi, T., Ogata, H., Takaesu, G., Takaki, H., Hashimoto, M., Yagita, H., Nawata, H. & Yoshimura, A. (2006) Suppressor of cytokine signaling-1 regulates inflammatory bowel disease in which both IFNγ and IL-4 are involved. Gastroenterology 130, 373-388.
4. Emanuelli, B., Peraldi, P., Filloux, C., Chavey, C., Freidinger, K., Hilton, D.J., Hotamisligil, G.S. & Van Obberghen, E. (2001) SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-α in the adipose tissue of obese mice. J. Biol. Chem. 276, 47944-47949.
5. Emanuelli, B., Peraldi, P., Filloux, C., Sawka-Verhelle, D., Hilton, D. & Van Obberghen, E. (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J. Biol. Chem. 275, 15985-15991.
6. Hagihara, K., Nishikawa, T., Sugamata, Y., Song, J., Isobe, T., Taga, T. & Yoshizaki, K. (2005) Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expression. Genes Cells 10, 1051-1063.
7. Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C.Z., Uysal, K.T., Maeda, K., Karin, M. & Hotamisligil, G.S. (2002) A central role for JNK in obesity and insulin resistance. Nature 420, 333-336.
8. Hotamisligil, G.S., Peraldi, P., Budavari, A., Ellis, R., White, M.F. & Spiegelman, B.M. (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science 271, 665-668.
9. Inoue, H., Ogawa, W., Asakawa, A. et al. (2006) Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 3, 267-275.
10. Inoue, H., Ogawa, W., Ozaki, M. et al. (2004) Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 10, 168-174.
11. Jamieson, E., Chong, M.M., Steinberg, G.R., Jovanovska, V., Fam, B.C., Bullen, D.V., Chen, Y., Kemp, B.E., Proietto, J., Kay, T.W. & Andrikopoulos, S. (2005) Socs1 deficiency enhances hepatic insulin signaling. J. Biol. Chem. 280, 31516-31521.
12. Kahn, C.R. (1994) Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43, 1066-1084.
13. Kawazoe, Y., Naka, T., Fujimoto, M., Kohzaki, H., Morita, Y., Narazaki, M., Okumura, K., Saitoh, H., Nakagawa, R., Uchiyama, Y., Akira, S. & Kishimoto, T. (2001) Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J. Exp. Med. 193, 263-269.
14. Kim, H.J., Higashimori, T., Park, S.Y., Choi, H., Dong, J., Kim, Y.J., Noh, H.L., Cho, Y.R., Cline, G., Kim, Y.B. & Kim, J.K. (2004) Differential effects of interleukin-6 and-10 on skeletal muscle and liver insulin action in vivo. Diabetes 53, 1060-1067.
15. Klover, P.J., Zimmers, T.A., Koniaris, L.G. & Mooney, R.A. (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52, 2784-2789.
16. Lehmann, U., Schmitz, J., Weissenbach, M., Sobota, R.M., Hortner, M., Friederichs, K., Behrmann, I., Tsiaris, W., Sasaki, A., Schneider-Mergener, J., Yoshimura, A., Neel, B.G., Heinrich, P.C. & Schaper, F. (2003) SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J. Biol. Chem. 278, 661-671.
17. Liu, H., Ma, Y., Cole, S.M., Zander, C., Chen, K.H., Karras, J. & Pope, R.M. (2003) Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 102, 344-352.
18. Manley, P.N., Ancsin, J.B. & Kisilevsky, R. (2006) Rapid recycling of cholesterol: The joint biologic role of C-reactive protein and serum amyloid A. Med. Hypotheses 66, 784-792.
19. Netea, M.G., Joosten, L.A., Lewis, E. et al. (2006) Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat. Med. 12, 650-656.
20. Nicholson, S.E., De Souza, D., Fabri, L.J., Corbin, J., Willson, T.A., Zhang, J.G., Silva, A., Asimakis, M., Farley, A., Nash, A.D., Metcalf, D., Hilton, D.J., Nicola, N.A. & Baca, M. (2000) Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. USA 97, 6493-6498.
21. Oike, Y., Akao, M., Kubota, Y. & Suda, T. (2005) Angiopoietin-like proteins: Potential new targets for metabolic syndrome therapy. Trends Mol. Med. 11, 473-479.
22. Pepys, M.B. & Hirschfield, G.M. (2003) C-reactive protein: A critical update. J. Clin. Invest. 111, 1805-1812.
23. Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E. & Ridker, P.M. (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286, 327-334.
24. Roberts, A.W., Robb, L., Rakar, S., Hartley, L., Cluse, L., Nicola, N.A., Metcalf, D., Hilton, D.J. & Alexander, W.S. (2001) Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl. Acad. Sci. USA 98, 9324-9329.
25. Rui, L., Yuan, M., Frantz, D., Shoelson, S. & White, M.F. (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277, 42394-42398.
26. Senn, J.J., Klover, P.J., Nowak, I.A. & Mooney, R.A. (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51, 3391-3399.
27. Senn, J.J., Klover, P.J., Nowak, I.A., Zimmers, T.A., Koniaris, L.G., Furlanetto, R.W. & Mooney, R.A. (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J. Biol. Chem. 278, 13740-13746.
28. Shi, H., Tzameli, I., Bjorbaek, C. & Flier, J.S. (2004) Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J. Biol. Chem. 279, 34733-34740.
29. Steppan, C.M., Wang, J., Whiteman, E.L., Birnbaum, M.J. & Lazar, M.A. (2005) Activation of SOCS-3 by resistin. Mol. Cell. Biol. 25, 1569-1575.
30. Ueki, K., Kondo, T. & Kahn, C.R. (2004a) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 24, 5434-5446.
31. Ueki, K., Kondo, T., Tseng, Y.H. & Kahn, C.R. (2004b) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc. Natl. Acad. Sci. USA 101, 10422-10427.
32. Visser, M., Bouter, L.M., McQuillan, G.M., Wener, M.H. & Harris, T.B. (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA 282, 2131-2135.
33. Wallenius, V., Wallenius, K., Ahren, B., Rudling, M., Carlsten, H., Dickson, S.L., Ohlsson, C. & Jansson, J.O. (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 8, 75-79.
34. Wang, Z., Jiang, B. & Brecher, P. (2002) Selective inhibition of STAT3 phosphorylation by sodium salicylate in cardiac fibroblasts. Biochem. Pharmacol. 63, 1197-1207.
35. Yasukawa, H., Ohishi, M., Mori, H., Murakami, M., Chinen, T., Aki, D., Hanada, T., Takeda, K., Akira, S., Hoshijima, M., Hirano, T., Chien, K.R. & Yoshimura, A. (2003) IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4, 551-556.
36. Yasukawa, H., Sasaki, A. & Yoshimura, A. (2000) Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18, 143-164.
37. Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.W., Karin, M. & Shoelson, S.E. (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293, 1673-1677.
38. Zhang, D., Sun, M., Samols, D. & Kushner, I. (1996) STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J. Biol. Chem. 271, 9503-9509.